And with that, I might now like to show the decision over to Joseph C. Papa. Joe?
Joseph C. Papa: Thanks, Frank, and hi there, everybody. Welcome to Emergent’s third quarter 2025 Earnings Name. That is Joseph C. Papa, CEO of Emergent, and I am joined right now by Richard S. Lindahl, our Chief Monetary Officer. We’ll begin by offering third quarter highlights after which Wealthy will evaluate the third quarter financials. I am going to return to evaluate key enterprise catalysts to drive progress. We’ll shut with a Q&A session. Turning to Slide 5, the Emergent crew’s aspiration is to be the chief in fixing public well being crises world wide. As a part of our mission to guard and save lives, we develop and ship extremely complicated merchandise to handle among the world’s most urgent threats.
Based mostly on the efforts of our crew, we had one other nice quarter and are on monitor to exceed our preliminary 2025 income and adjusted EBITDA steering. 12 months up to now, now we have secured 11 contract modifications and product orders for our Biodefense enterprise whereas sustaining our market management place within the nasal naloxone class. We have now a sturdy Biodefense Enterprise Mannequin with a North America-based provide chain for our product and manufacturing within the US or within the USMCA compliant facility. Lastly, we imagine our differentiated capabilities in plasma and hard-to-manufacture merchandise place us to be a strategic long-term accomplice for our clients. Turning to Slide six, Emergent was based 25 years in the past, and our enterprise is in contrast to conventional pharmaceutical corporations.
Actually, now we have essentially the most diversified biodefense and naloxone product portfolio. It’s targeted on addressing the worldwide public well being threats of smallpox, anthrax, ten pox, Ebola, botulism, and even opioid overdose emergency conditions. Simply yesterday, we launched a brand new survey discovering that strengthened bioterrorism stays a major concern to knowledgeable public coverage leaders. Turning to slip eight, we’re making nice progress with our multi-year transformation. Throughout 2025, we proceed to make strategic investments for long-term progress whereas creating vital worth for our stakeholders. We’re reaching working margin enhancements and validating greatest choices to advance top-line progress whereas sustaining our engaging price construction.
On Slide 9, we offer a extra detailed have a look at the third quarter, together with exceeding our inside steering on each the highest and backside line. Third quarter revenues of $231 million have been $21 million above the excessive finish of our Q3 steering vary of $180 million to $210 million. Our profitability continues to enhance, and yr up to now, now we have already achieved the excessive finish of our full-year adjusted EBITDA steering vary of $194 million generated as of the third quarter. Each the income and profitability of the enterprise exceeded our inside administration expectations and the analyst consensus.
Based mostly on the year-to-date efficiency, we’re growing our adjusted EBITDA steering vary to $195 million to $210 million, up from $175 million to $200 million. Our liquidity stays very sturdy. We now have entry to $346 million in monetary capability to spend money on extra progress and capital deployment. This consists of $246 million of stability sheet money and our undrawn revolver. We’re happy with the numerous assortment of money for accounts receivable even throughout the first day in This fall. We’re selectively deploying our capital to create stakeholder worth. Our internet leverage improved to roughly 2x internet debt to adjusted EBITDA, down from 3.3 instances in 2024. In 2025, we have additionally repurchased some Emergent bonds.
It continues with our share repurchase program the place we count on $15.8 million of our $50 million twelve-month program. We’re excited in regards to the progress within the NCM section with 4 new contract modifications added within the third quarter. We additionally see upside from our worldwide clients, which signify 34% of our MCM gross sales yr up to now, which is up from the mid to excessive teenagers in previous years. Our management in Naloxone stays sturdy, and we’re dedicated as ever to fight the opioid overdose epidemic and saving lives. With two months left within the yr, we really feel excellent about our 2025 efficiency and are actively working to ascertain extra progress drivers for 2026 and past.
On Slide 10, we summarize the sturdy efficiency of our Naloxone enterprise yr up to now. We stay the chief within the naloxone class amongst public curiosity clients. We’re benefiting from a stabilized U.S. pricing marketplace for naloxone. Quarter over quarter, NARCAN unit quantity grew by 13% and income grew by 9%. This sequential progress reaffirms that now we have moved previous one-time first quarter occasions. Actually, NRPM demand stays sturdy. We count on continued progress of your entire market, which can present a tailwind to our enterprise. Now I would like to show the decision over to Wealthy to stroll via the third quarter financials.
Richard S. Lindahl: Thanks, Joe. Good afternoon, everybody. We recognize you becoming a member of the decision. We’re off to a powerful begin in 2025. Our third quarter income got here in at $231 million, exceeding the higher finish of our steering vary by $21 million, pushed by sequential progress of NARCAN and the addition of 4 new contract modifications. By means of the third quarter, we proceed to see year-over-year enhancements in each gross margin and adjusted EBITDA margin, highlighting the effectivity of our enterprise that delivered a 38% adjusted EBITDA margin this previous quarter. To additional spotlight our sturdy efficiency, internet revenue for the third quarter was $51 million. 12 months-to-date internet revenue was $107 million, and year-to-date earnings per share was $1.89.
12 months-to-date efficiency has additionally exceeded our inside expectations. We’re elevating our complete income steering to a variety of $775 million to $835 million, a $5 million enchancment on the midpoint. And we’re growing our adjusted EBITDA steering to a variety of $195 million to $210 million, a $15 million improve on the midpoint as in comparison with our prior forecast. The profitability and money technology of our firm has allowed us to give attention to creating alternatives to generate extra shareholder worth. Within the third quarter, we deployed money in the direction of each fairness and debt, benefiting from opportunistic pricing. Even with these actions, our money place and leverage ratio remained in a powerful and steady place.
Each of our enterprise segments outperformed within the quarter, and importantly, we noticed no disruption from exterior macro components which may be pressuring the remainder of biopharma. We proceed to play a significant function as a trusted accomplice to each the U.S. Authorities and our worldwide companions, with rising demand for our medical countermeasures as nations prioritize preparedness and response capabilities. Please flip to Slide 12 to evaluate our third quarter financials. I am going to begin by noting that the prior yr comparisons totally replicate our restructuring actions from early 2024. Highlights of the quarter embrace complete revenues of $231 million. As a reminder, third quarter 2024 benefited from a partial quarter of non-divested revenues from RSTL and the Camden facility.
Adjusted EBITDA margin of 38%, a rise of 200 foundation factors versus the prior yr, underscoring our continued sturdy profitability with our environment friendly platform. Adjusted gross margin of 61% improved 200 foundation factors yr over yr, pushed by a extra favorable product combine, the enlargement of strategic international partnerships, and a leaner price construction stemming from our divestitures and restructuring initiatives. And eventually, working bills of $52 million have been $38 million decrease in comparison with the prior yr. Of word, you possibly can see that our SG&A spend declined roughly 50% from LiveSolver. Further third quarter income particulars might be discovered within the appendix. Turning to Slide 13, I am going to stroll via our efficiency for the primary 9 months of 2025.
Complete revenues have been $594 million, a decline in comparison with the prior yr, reflecting the divestitures, the J&J one-time settlement in 2024, and strategic pricing actions taken on NARCAN. Adjusted EBITDA was $194 million or 33% of complete revenues, an enchancment of roughly $32 million and 1,400 foundation factors yr over yr. This consequence illustrates our sturdy working leverage, the impression of our restructuring actions, in addition to a good product combine in 2025 pushed by worldwide MCM gross sales. Adjusted gross margin of 57% improved 1,100 factors in comparison with the prior yr. This enlargement was pushed by product combine and continued operational efficiencies stemming from the 2024 initiatives. Working bills totaled $176 million, a $133 million discount from the prior yr.
Most of this discount got here from a $112 million decline in SG&Some time we preserved important R&D capabilities to help long-term progress. Transferring on to Slide 14. For the primary 9 months of 2025, complete income was $594 million, pushed by complete product gross sales of $545 million. As famous, 2024 consists of income related to one-time occasions and belongings. The desk within the higher proper nook of Slide 14 normalizes 2024 income for this stuff. With that, let’s break down efficiency by key product strains. Naloxone nasal spray income totaled $188 million, reflecting improved sequential momentum from the second and third quarters. Anthrax medical countermeasure income was $61 million based mostly on the timing of presidency procurement orders.
Smallpox income was $231 million, a rise of $30 million or 15%, reflecting deliveries below multiyear contracts and elevated worldwide orders. Lastly, different revenues have been $49 million. As a reminder, final yr’s revenues included $50 million from the Janssen settlement in addition to Camden facility income previous to its divestiture in August 2024. Normalizing for this stuff, different revenues grew $25 million yr over yr, attributable to elevated providers demand in our Winnipeg facility, together with CNG income associated to our Givanga growth program. Turning to Slide 15, I am happy to report continued progress in strengthening our monetary place. For 2025, complete liquidity was $346 million, comprised of $246 million of money and $100 million of undrawn revolver capability.
Liquidity improved $96 million yr over yr. As of September 30, our gross debt was $693 million, down about $7 million versus the prior yr, pushed by our unsecured bond repurchases throughout the quarter. Complete internet debt in Q3 2025 was $448 million, a $103 million or 19% discount. Our internet leverage remained within the 2x adjusted EBITDA vary on the finish of the third quarter, as we each elevated profitability and lowered gross debt. We additionally collected vital accounts receivable from late September MCM deliveries in early October, regardless of the present U.S. Authorities shutdown, additional enhancing our working money stream. This consequence additional reinforces the significance of our enterprise. Please flip to Slide 16.
Our capital allocation priorities are targeted on three key areas: progress, debt reimbursement, and share repurchases. First, we’re investing in each natural and inorganic alternatives to strengthen our core companies and drive future income enlargement. Some vital tailwinds embrace growing worldwide income from our Medical Countermeasures section and our stronger stability sheet, which permits enterprise growth. We stay very considered stewards of shareholder capital and proceed to guage alternatives to advance inside R&D tasks. Subsequent, we proceed to prioritize debt reimbursement to strengthen our stability sheet and enhance monetary flexibility. Starting in August, we initiated a $30 million bond repurchase program and throughout the quarter retired $6.9 million in principal quantity of unsecured bonds for $5.8 million of money.
We’re additionally dedicated to creating shareholder worth via the twelve-month $50 million share repurchase program we introduced in March 2025. Within the third quarter, we repurchased one other 1.1 million shares for $8.9 million, bringing us to 2.3 million repurchased yr up to now for $15.8 million or a mean value of $7 per share. We stay opportunistic with buybacks in future quarters as we consider market situations and different components. Transitioning to Slide 17, we’re updating our full-year 2025 steering by elevating the midpoint of our income and profitability metrics.
Additional particulars are as follows: complete revenues of $775 million to $835 million, a rise of $5 million on the midpoint; adjusted EBITDA within the vary of $195 million to $210 million, an enchancment of $15 million on the midpoint. We’re additionally elevating our adjusted gross margin steering to a variety of 52% to 54%, a 200 foundation level enchancment over our prior steering on the midpoint. On the sturdy efficiency yr up to now throughout our segments, we’re additionally elevating the midpoint of our medical countermeasures product income steering whereas sustaining our prior steering vary for business merchandise. Section income steering is as follows: NCM product gross sales are $450 million to $475 million.
We proceed our enduring partnership with the U.S. Authorities, which is additional evidenced by the 11 contract modifications we have obtained yr up to now for our medical countermeasure merchandise. Business merchandise, together with KLXSATA, the vary of $265 million to $300 million. 12 months up to now, business product gross sales have been $188 million with steady pricing throughout the U.S. public curiosity channel. Our efficiency in 2025 reinforces our market-leading place within the opioid overdose reversal house. In closing, on Slide 18, we’re persevering with the turnaround part of our multi-year plan with stable efficiency within the first 9 months of 2025. Our 2025 income outlook stays targeted on our core enterprise throughout each the medical countermeasures and business segments.
Of word, worldwide gross sales now signify 34% of the corporate’s MCM section, which is up meaningfully from the excessive teenagers in prior years. We’re carefully monitoring this development and making focused investments to facilitate this progress. Our partnership with the U.S. Authorities and worldwide clients stays sturdy, as evidenced by the 11 contract modifications yr up to now. Our gross margins and profitability have continued to enhance all year long, and we’re producing optimistic working money stream whereas enhancing our liquidity place. Our leverage ratio is steady at roughly 2x adjusted EBITDA. Trying forward, our plan stays constant. We’re pursuing strategic progress investments whereas actively looking for alternatives to ship worth to our shareholders.
I am going to now flip the decision again to Joe to debate our enterprise outlook and catalysts. Joe?
Joseph C. Papa: Thanks, Wealthy. Turning to Slide 20. Let’s start with our naloxone enterprise. Our complete Emergent group is pleased with the tangible impression that Narcan has in saving many lives from opioid overdoses in america and Canada. Subsequent month, we are going to acknowledge the ten-year anniversary of the U.S. approval of the prescription NARCAN nasal spray. We’ll spotlight the super work that’s going to increase entry via its over-the-counter availability in 2023.
And with ongoing efforts to increase Narcan entry, added Foxado into our NARCAN DIRECT platform for ease of buying, mixed with the over $50 billion in opioid litigation settlement {dollars}, we imagine that our portfolio will proceed to align with the general internet market progress expectations. Transferring to slip quantity 41, I would wish to evaluate the important thing outcomes from our latest Biodefense survey. There’s vital bipartisan help favoring biothreat preparedness. The underside line is that after coverage opinion leaders, the perceived threat of bioterror threats is excessive, and bioterrorism even outpaces considerations about nuclear threat. It is because organic assaults are considered to be extra possible, extra imminent. These surveyed have been involved in regards to the general preparedness.
This quarter, we secured 4 new U.S. Authorities contracts price roughly $155 million mixed. We additionally efficiently secured an incremental $29 million of MCM product orders with a world authorities accomplice. Worldwide gross sales have been a key progress driver in 2025 and signify 34% of our MCM gross sales yr up to now, which is meaningfully greater than prior years. On the general public gross sales entrance, Emergent was in steady communication with our Evanga business accomplice, Ridgeback Therapeutics. Ridgeback, together with different organizations and native well being authorities, immediately supported efforts throughout the latest Ebola outbreak within the Democratic Republic of Congo.
This outbreak, which is one in every of a number of over the past 5 years, is a stark reminder of the continued frequency and menace of the Ebola virus illness. International readiness and resilience are key to being ready for the subsequent potential outbreak. Earlier this yr, we introduced our continued collaboration with BARDA to advance Evanga growth in the direction of supplying remedy, guaranteeing we’re ready towards Ebola. On slide 22, we define our outlook on future progress and money deployment. Our plan is to speculate the money we’re producing from our worthwhile enterprise segments into two progress tracks. First, exploring authorities collaborations for brand new biodefense merchandise.
The second is to establish value-creating exterior business applications that align strategically with their present enterprise mannequin and capabilities. In abstract, on slide quantity 25, now we have adjusted, now we have outperformed our top-line and adjusted EBITDA steering expectations within the third quarter. We’re elevating our full-year income steering whereas additionally elevating our adjusted EBITDA steering to $195 million to $210 million. All through 2025, our working margin and money stream have grown considerably as we execute our multi-year turnaround plan. In conclusion, now we have a singular and diversified biodefense portfolio. We’re proud leaders addressing the overdose epidemic via our life-saving naloxone merchandise.
We’ll take extra steps to generate worth for all our stakeholders, and we are going to attempt for the very best requirements of high quality, ethics, and compliance throughout your entire Emergent enterprise. So with that, I stay up for taking your questions. Operator, if you happen to please open up the road for questions.
Operator: Thanks. Presently, we are going to conduct a query and reply session. As a reminder, to ask a query, you’ll need to press 11 in your phone and wait on your title to be introduced. To withdraw your query, please press 11 once more. Our first query comes from the road of Jessica Macomber Fye from JPMorgan. The ground is yours.
Jessica Macomber Fye: Hey, guys. Good afternoon. Thanks for taking my questions. I’ve a number of. First, what drove the sturdy year-over-year progress in different merchandise particularly? Second, with worldwide driving 34% of MCM orders yr up to now, can we consider these orders as recurring? Are they a part of multiyear contracts? Or are they one-off orders? And may you remind me how the gross margin on worldwide MCM orders compares to the gross margin related to US MCM gross sales? Then for Narcan, you talked about OTC gross sales and Canadian gross sales fell yr over yr. What are you seeing in every of these segments of the enterprise? And may we take into account any impression from the federal government shutdown on the NARCAN enterprise this quarter?
And what in regards to the MCM enterprise? Thanks.
Joseph C. Papa: Okay. There’s fairly a bit there, Jessica. Thanks for the questions. We must always take the primary one a part of the button below your class. It is there. Yeah. So a whole lot of it’s pushed by agreements with the Evanga program having vital exercise this yr. And that is actually in all probability the key driver there. I feel the second query you had about our worldwide contracting and is {that a} recurring income base and a couple of time. We have labored very diligently over the past eighteen months the place we made some investments in our worldwide platform to achieve out and get extra worldwide income and gross sales. And I am glad to say that, that’s paying off and we’re seeing that.
So we view this as a part of a concentrated program and exercise. Admittedly, any given contract is for a set quantity of product in a set period of time. However we clearly see the worldwide alternative as one which can be a progress alternative for us sooner or later. So in all probability the very best reply is these merchandise are definitely a part of a selected order for a selected amount and a selected time.
However we do view this as being a world progress alternative, particularly as we all know the European Union and different elements of the world are persevering with to ramp up their capabilities on this complete space of biodefense and strategic nationwide stockpile that they are establishing in our crew has been delighted to attempt to assist them as they prepare for this European Union stockpiling program on strategic nationwide dimension consciousness. Going to assist them to assume via that sort of course of. On the subsequent a part of your query, the worldwide gross margin, and one of many issues I might say is, are worldwide gross margins greater? The reply to that’s sure.
And one of many points that now we have is that now we have dedicated to the U.S. Authorities and that they’ve helped us with our funding. For our applications and our merchandise, that they’d U.S. Authorities would get what we consult with as most segregation pricing. So on account of that, they often get the very best value and different international locations pay, a bit bit extra. It isn’t a giant market distinction, however there’s a little bit higher pricing for the U.S. Authorities in that they helped us with the event of our merchandise. The following query I imagine was NARCIA and in Canada and what’s taking place there. We’re making good progress.
We have talked about a lot of totally different venture agreements that now we have with Canadian provinces and making good progress there. I might say that is one thing that is going to be variable in any given quarter when it comes to when gross sales occur within the third quarter, the fourth quarter, or subsequent yr. However we’re making excellent progress in Canada is recognizing that they have points with opioid overdoses, they’re trying to us to assist them fulfill a few of that demand on the market. So, we’re making progress there.
There’s going to be some variability quarter over quarter when it comes to when the quarter will get shipped in third quarter, fourth quarter, or first quarter, however we’re very pleased with the connection now we have with the Canadian authorities. Last query I feel you had was authorities shutdown. And I can inform you first hand, the US authorities workers that we work with on the Strategic Nationwide Stockpile of BARDA Division of Protection, proceed to work day by day and so they’re going above and past to name responsibility when it comes to what they’re doing however the shutdown.
And I can inform you first hand, Wealthy, myself, the remainder of our crew had a gathering with the very best ranges of BARDA Division of Protection, and Strategic Nationwide Stockpile simply final week. So the whole lot we see is a steady to maneuver ahead on these vital strategic initiatives that when it comes to what the Biodefense Constructing represents in The U.S. is vital. Should do actions. So that they hold working exhausting and clearly there to help them any means we are able to. I feel I obtained all of them, Jessica, however thanks on your query. Operator, subsequent individual.
Operator: Oh, sure. Our subsequent query comes from Raghuram Selvaraju from H.C. Wainwright and Co. The ground is yours.
Eduardo Rafael Martinez-Montes: Hello, everybody. That is Eduardo on for Ram. Hoping to get a bit replace on the Rocketbats collaboration, in case you have any significant catalyst over the subsequent twelve months?
Joseph C. Papa: Certain. Only a reminder for everyone. Earlier within the yr, we reached with Swiss Rocket, the pair Rocket Vaxx to work with them on 4 venture alternatives. They’re making good progress. On the primary product that we have acknowledged, they do have funding for the Part one in every of that. Analysis that they are now acquiring the preliminary amount of medical trial materials. I feel that trial began. Expectation that the trial will begin someday within the early a part of 2026. And I remind you, what we imagine is absolutely vital with the boxing bag expertise is that it’s totally different than the mRNA expertise. It’s not mRNA.
However it’s a quick to develop expertise however it makes use of stay attenuated virus expertise, vaccine expertise. And by doing that, it could possibly be developed shortly, just like mRNA. Nonetheless, there’s sturdiness within the immune response as a result of they use a stay attenuated model. So that is what we’re enthusiastic about. As a result of it falls below one thing known as Undertaking Subsequent Gen. Because the U.S. Authorities is in search of the subsequent virus outbreak, how might or not it’s managed, and so they view one of these expertise as being probably vital to that subsequent wave of outbreaks, no matter pandemic it may be. So, sure, quickly making progress. We’re working with them.
There’s nonetheless a whole lot of work to be doing, however they’ve the funding for the Part one beginning someday in 2026. Okay. Subsequent query.
Operator: Thanks for that query. Is there one other query you’d wish to ask?
Eduardo Rafael Martinez-Montes: Certain. Yeah. May I get simply kinda curious extra on the NCM merchandise this time. Which of the merchandise do you assume is gonna be the principal driver of US authorities contract-based income going ahead? And do you’ve any concepts why that may be?
Joseph C. Papa: Yeah. I feel the benefit that we at Emergent have is now we have essentially the most diversified product portfolio within the biodefense world. And all of us acknowledge that the biodefense class is we’re residing in an more and more harmful world, the expertise as we confirmed in our survey in biodefense is one thing that could possibly be in a short time rolled out by some terrorists. Teams. So we predict it is vital that we’re ready. I feel it actually comes all the way down to for us, it is simply having this range of the portfolio in order that we’re prepared for any potential exercise we work very carefully with BARDA, Strategic Nationwide Stockpile, Division of Protection to make sure no matter occurs that we’re ready to assist them.
And we’re working very carefully with them. So we meet with them regularly to get ready. So I do not know if I need to pick a singular product. I feel they’re all vital to us. And I feel what’s in all probability crucial factor about when you consider Emergent is the range now we have, whether or not or not it’s merchandise for smallpox, whether or not or not it’s a vaccine or a therapeutic merchandise for anthrax, whether or not or not it’s the vaccine or therapeutic merchandise for botulism. We have got throughout the top merchandise. We have now all of them. And I feel that is what actually actually units us other than the opposite gamers within the house.
Clearly, within the new class, we like the chance with Cimbexa. Will we see the persevering with outbreaks of Ebola? Sure, these are vital issues for us as properly. I feel they will drive a giant a part of our future. Thanks for the query.
Operator: Thanks on your query. This concludes the query and reply session. I might now like to show it again to Joseph C. Papa, CEO, for closing remarks.
Joseph C. Papa: Nicely, thanks, everybody, for becoming a member of us right now. We very a lot recognize your curiosity in our firm. Please attain out if there’s every other extra questions. However we’re enthusiastic about what Emergent is conducting this yr. I feel we’re properly on our solution to have one other good yr for us and one other nice quarter. And really a lot due to all working at Emergent for all of the work they’ve executed to assist us have a really sturdy yr up to now. Thanks, everybody, for becoming a member of us right now. Have an incredible day.
Operator: Thanks on your participation in right now’s convention. This does conclude this system. You could now disconnect.
Ever really feel such as you missed the boat in shopping for essentially the most profitable shares? Then you definitely’ll need to hear this.
On uncommon events, our skilled crew of analysts points a “Double Down” inventory suggestion for corporations that they assume are about to pop. Should you’re anxious you’ve already missed your probability to speculate, now’s the very best time to purchase earlier than it’s too late. And the numbers converse for themselves:
-
Nvidia: if you happen to invested $1,000 after we doubled down in 2009, you’d have $536,975!*
-
Apple: if you happen to invested $1,000 after we doubled down in 2008, you’d have $51,258!*
-
Netflix: if you happen to invested $1,000 after we doubled down in 2004, you’d have $593,442!*
Proper now, we’re issuing “Double Down” alerts for 3 unimaginable corporations, accessible whenever you be a part of Inventory Advisor, and there is probably not one other probability like this anytime quickly.
See the three shares »
*Inventory Advisor returns as of October 27, 2025
This text is a transcript of this convention name produced for The Motley Idiot. Whereas we attempt for our Silly Greatest, there could also be errors, omissions, or inaccuracies on this transcript. As with all our articles, The Motley Idiot doesn’t assume any accountability on your use of this content material, and we strongly encourage you to do your individual analysis, together with listening to the decision your self and studying the corporate’s SEC filings. Please see our Phrases and Situations for extra particulars, together with our Compulsory Capitalized Disclaimers of Legal responsibility.
The Motley Idiot recommends Emergent BioSolutions. The Motley Idiot has a disclosure coverage.
Emergent BioSolutions (EBS) Earnings Transcript was initially printed by The Motley Idiot